Aspirologo.jpg (Aspirologo)
Fosaprepitant Injection, Powder, Lyophilized, For Solution
Product Images NDC 31722-165
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Fosaprepitant (NDC 31722-165). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Camber Logo (Camber Logo)
Fosaprepinjcarton (Fosaprepinjcarton)
This is a description of Fosaprepitant for injection, which comes in 150mg vials and is used intravenously. It is reconstituted using 5 mL of 0.9% Sodium Chloride for Injection and should not be used with solutions containing divalent cations. The inactive ingredients include edetate disodium, lactose anhydrous, polysorbate 80, sodium hydroxide and/or hydrochloric acid. This medication should be refrigerated when not in use and should be discarded after use. The manufacturer is Camber Pharmaceuticals, Inc. and the product is intended for single use only. There is information available for patients online.*
Fosaprepinjlabel (Fosaprepinjlabel)
This is a description of Fosaprepitant, a drug provided in a single-dose vial containing 150mg, for intravenous use only after reconstitution and dilution. It should be stored refrigerated at 29C to 8°C (36°F to 46°F), and the reconstituted solution stable for 24 hours at ambient room temperature [at or below 25°C (77°F)]. A usual dosage is noted, but no specific details provided. The manufacturer is Camber Pharmaceuticals, Inc. of Piscataway, NJ 08854, and this drug is produced by ASPIRO PHARMA LIMITED in India.*
Structure.jpg (Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
